Results 31 to 40 of about 673,470 (204)
Clinical Microbiology and Infection, 2022 OBJECTIVES Serogroup W and Y invasive meningococcal disease (IMD) increased globally from 2000 onwards. Responding to a rapid increase in serogroup W clonal complex 11 (W:cc11) IMD, the UK replaced an adolescent booster dose of meningococcal C conjugate ...
J. Carr +37 more
semanticscholar +1 more source
Pediatric Infectious Disease Journal, 2004 The 5 major pathogenic serogroups of the Gram-negative encapsulated bacterium Neisseria meningitidis are A, B, C, Y, and W135. In the 1960s, vaccines consisting of purified capsular polysaccharide antigens were developed against serogroups A, C, Y, and W135.
Rüggeberg, J, Pollard, A
openaire +6 more sources
Promising pharmaceutical development of vaccines for the prevention of meningococcal infection
Журнал микробиологии, эпидемиологии и иммунобиологии, 2023 Meningococcal infection (MI) refers to anthroponoses; is an acute infectious disease with an aerosol transmission mechanism, characterized by various forms of the infectious process: from local (nasopharyngitis) and asymptomatic infections to generalized
Maria V. Savkina +3 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2012 Meningococcal meningitis is caused by Neisseria meningitidis, a gram-negative, aerobic, encapsulated diplococcus. Meningococci are divided into numerous serogroups based on the composition of their capsular polysaccharide (Ps) antigens. At least 13 serogroups have been described: A, B, C, D, 29E, H, I, K, L, W-135, X, Y and Z.
Ramesh, Verma, Pardeep, Khanna
openaire +2 more sources
Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
Journal of Infection, 2020 Serogroup B meningococci (MenB) remain a prominent cause of invasive meningococcal disease (IMD). The protein-based multicomponent 4CMenB and the bivalent MenB-FHbp are the only currently available vaccines against MenB-caused IMD.
R. Borrow +5 more
semanticscholar +1 more source
Correlates of protection for meningococcal surface protein vaccines: lessons from the past
Expert Review of Vaccines, 2021 Introduction Recombinant surface protein meningococcal serogroup B (MenB) vaccines are available but with different antigen compositions, leading to differences between vaccines in their immunogenicity and likely breadth of coverage.
J. Findlow +4 more
semanticscholar +1 more source
mSphere, 2018 Neisseria meningitidis is a common cause of bacterial meningitis in children and young adults worldwide. The 4CMenB vaccine (Bexsero), developed to combat meningococcal serogroup B (MenB) disease, contains subcapsular antigens that may induce immunity ...
Robert M. Mulhall +12 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 Vaccination offers the best way to prevent invasive meningococcal disease (IMD). As demonstrated in countries with national immunization programs (NIPs) against IMD, meningococcal conjugate vaccines have contributed to significant declines in incidence ...
Gary S. Marshall +3 more
doaj +1 more source
Meningococcal glycoconjugate vaccines [PDF]
Human Vaccines, 2011 Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies. In the past, plain polysaccharide vaccines containing purified capsular polysaccharides A, C, Y and W135 were ...
GASPARINI, ROBERTO, PANATTO, DONATELLA
openaire +2 more sources
Infectious Diseases and Therapy, 2019 Neisseria meningitidis is a major cause of meningitis and septicemia with cases, outbreaks, and epidemics reported globally in industrialized and non-industrialized countries. N. meningitidis is categorized into 12 serogroups; however, only 5 serogroups (
Jessica Presa +4 more
doaj +1 more source